You searched for rivaroxaban - MPR

Your search for rivaroxaban returned 78 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove

Your search for rivaroxaban returned 78 results

Sort Results:

Relevant Recent
American College of Cardiology 2013

Similar Bleeding and Thrombotic Complication Rates Between Dabigatran and Rivaroxaban

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Anil Rajendra, MD, from the Medical University of South Carolina, in Charleston, SC, presented data showing similar bleeding and thrombotic complication rates at the time of atrial fibrillation ablation (AFA) in patients anticoagulated with dabigatran and rivaroxaban. Dr. Rajendra and colleagues determined that rivaroxaban has an acceptable safety profile for AFA.
News

Food Type, Timing Has No Clinically Relevant Impact on Rivaroxaban

Currently, the prescribing information recommends 20mg once daily with an evening meal for the AF indication, and 15mg twice daily with food for 21 days, followed by 20mg once daily with food for the remainder of treatment for the DVT/PE indications.
News

Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With VTE

Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
American College of Cardiology 2013

Net Clinical Benefit of Rivaroxaban for Thrombosis Prevention in ACS Patients

After reports of having met the primary endpoints in the ATLAS-ACS TIMI-52 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.
Drugs in the Pipeline

Phase 3 Study of Xarelto for Treatment and Secondary Prevention of Venous Blood Clots

Janssen Research & Development announced results of the EINSTEIN-PE study showing that Xarelto (rivaroxaban) was comparable to today's standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).